top of page
Revolutionizing Diagnostics:
Imaging for Eye and Neurological Health
Earlier, Smarter Detection for Alzheimer's
& Degenerative Eye Diseases
Standard fundus photography captures surface-level structure.
Optina captures biochemical nuance.
Our hyperspectral platform captures rich retinal data in seconds, uncovering microvascular shifts long before irreversible damage occurs.
High-Dimensional Hyperspectral Data
Captures a continuous spectral signature of retinal layers, uncovering subtle optical signatures invisible to standard white-light and monochromatic systems.
AI-Powered Biomarker Analysis
Proprietary machine learning models process complex spectral profiles against validated clinical datasets, delivering objective, reproducible diagnostic signals.
Non-Invasive, Rapid Patient Workflow
Designed for standard clinical environments—rapid capture, zero invasive contrast dyes, and immediate integration into diagnostic workflows.
OPTINA'S COMMERCIAL MOAT
FDA Cleared – 510k
Clinically validated for immediate integration into standard practice.
Reimbursement Ready
Utilizes existing diagnostic CPT codes for immediate clinic utilization.
FDA Breakthrough Device
Designated for accelerated impact in early detection of Alzheimer's.
IP Moat: 12 Global Patents
Comprehensive protection across proprietary optical systems and spectral AI.
What is Hyperspectral Imaging?
Data-rich image reveals key disease indicators invisible to current imaging modalities
Captures spatial and spectral data Hyperspectral Imaging
across 90 individual color bands in a 1-second, non-invasive scan
Increasing wavelengths sample deeper structures of the fundus
Unique Molecular, Functional and Anatomical Information
bottom of page